A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Qilu Pharmaceutical Co., Ltd.
University of California, Irvine
Merck Sharp & Dohme LLC
AstraZeneca
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Baylor College of Medicine
Amgen
Memorial Sloan Kettering Cancer Center
Kyowa Kirin Co., Ltd.
Ruijin Hospital
ImmunityBio, Inc.
NRG Oncology
Daiichi Sankyo
Nizhny Novgorod Regional Clinical Oncology Center
Laekna Limited
Sichuan Baili Pharmaceutical Co., Ltd.
AstraZeneca
University of Southern California
M.D. Anderson Cancer Center
Tesaro, Inc.
Astellas Pharma Inc
National University Hospital, Singapore
National Cheng-Kung University Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Memgen, Inc.
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.
Asan Medical Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NuCana plc
The Netherlands Cancer Institute
Jiangsu Hansoh Pharmaceutical Co., Ltd.
BeiGene
National Cancer Center, Japan
Ukrainian Society of Clinical Oncology
Hummingbird Bioscience
IGM Biosciences, Inc.
Karyopharm Therapeutics Inc
Australasian Gastro-Intestinal Trials Group
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Yonsei University
Peking University
Bruckner Oncology
BeiGene
Eli Lilly and Company
National Cancer Center Hospital East
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.